Technical Analysis for XRTXD - Xortx Therapeutics Inc

Grade Last Price % Change Price Change
F 3.02 -6.21% -0.2000
XRTXD closed down 6.21 percent on Friday, October 15, 2021, on approximately normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical XRTXD trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
New 52 Week Low Weakness 0.00%
Hot IPO Pullback Bullish Swing Setup -6.21%
Calm After Storm Range Contraction -6.21%
Narrow Range Bar Range Contraction -6.21%
NR7 Range Contraction -6.21%
NR7-2 Range Contraction -6.21%
Doji - Bullish? Reversal -6.21%
New 52 Week Closing Low Bearish -3.82%
Older End-of-Day Signals for XRTXD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day 6 days ago
Down 10% 6 days ago
Down 5% 6 days ago
Down 3% 6 days ago
Down 1% 6 days ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Xortx Therapeutics Inc Description

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medical Specialties Hypertension Anatomy Kidney Infection Kidney Disease Kidney Diseases Bio Pharmaceutical Insulin Resistance Organ Failure Acute Kidney Injury Diabetic Nephropathy Icahn School Of Medicine Progressive Kidney Diseases

Is XRTXD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 6.12
52 Week Low 2.9
Average Volume 173,911
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 4.6682
Average True Range 0.5671
ADX 0.0
+DI 23.0399
-DI 33.4748
Chandelier Exit (Long, 3 ATRs) 4.4187
Chandelier Exit (Short, 3 ATRs) 4.6013
Upper Bollinger Bands 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line -0.3715
MACD Signal Line -0.1380
MACD Histogram -0.2335
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.6950
Resistance 3 (R3) 3.7300 3.5400 3.5825
Resistance 2 (R2) 3.5400 3.3681 3.5225 3.5450
Resistance 1 (R1) 3.2800 3.2619 3.1850 3.2450 3.5075
Pivot Point 3.0900 3.0900 3.0425 3.0725 3.0900
Support 1 (S1) 2.8300 2.9181 2.7350 2.7950 2.5325
Support 2 (S2) 2.6400 2.8119 2.6225 2.4950
Support 3 (S3) 2.3800 2.6400 2.4575
Support 4 (S4) 2.3450